Pricing Log in Create free account
Saturday 17 October 2026 Export LEXX’s income statement to Excel — free account

Lexaria Bioscience Corp.

LEXX Healthcare Biotechnology

Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

2.92 0.07 −2.34%
Market cap
$6.3M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
4/9
Altman Z
−23.89
Beneish M
−3.56
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 6.30
Revenue 0.54
Net Income (7.74)
Free Cash Flow (7.53)
Net Debt (3.62)
Current Ratio 10.60 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (2.45) (negative: loss-making)
P/S ratio 8.91
P/B ratio 1.11
Past 5Y EPS Growth —
This Y EPS Growth 59.09% (at or above 15%: strong)
Next Y EPS Growth (14.81%) (below 0%: weak)
Next Y revenue growth (97.17%) (below 0%: weak)
Next 5Y EPS Growth 24.86% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.4×, against a ten-year median of 21.2×; over the ten years it ranged from −1.8× in 2020 to 117× in 2024.
P/S against its own 10 years 9.30%
10-year low 10-year high
P/B against its own 10 years 16.83%
10-year low 10-year high
EV/Sales against its own 10 years 4.02%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 7 2 4
Receivables 0 0 0 0
Inventory — — — —
Other — — — —
2 8 3 4
2023 2024 2025 Q'26
Payables 0 1 1 0
ST’ Debt — — — —
Other — — — —
0 1 1 0

Compound Annual Growth %

10y 5y 3y
Sales — 17.53% 40.34%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.95% (30.14%)

Revenue $m

Nov Feb May Aug Year
’26 — 0 — — —
’25 0 0 0 0 1
’24 0 0 0 0 0
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 0 0 0 0 1
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Nov Feb May Aug Year
’26 (1) (2) (2) — —
’25 (3) (1) (4) (3) (10)
’24 (1) (1) (1) (2) (5)
’23 (1) (1) (2) (2) (6)
’22 (1) (1) (1) (1) (5)
’21 (1) (1) (1) (1) (4)
’20 (1) (1) (1) (1) (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Nov Feb May Aug Year
’26 (1) (2) (2) — —
’25 (3) (2) (4) (3) (11)
’24 (1) (1) (1) (2) (5)
’23 (1) (1) (2) (2) (6)
’22 (1) (1) (1) (1) (5)
’21 (1) (1) (1) (1) (4)
’20 (1) (1) (1) (1) (3)
Fiscal quarters ending in the months shown.

EPS $

Nov Feb May Aug Year
’26 (1.05) (0.90) (1.20) — —
’25 (2.40) (2.25) (3.15) (1.95) (9.90)
’24 (1.95) (0.90) (1.95) (2.25) (7.05)
’23 (4.50) (3.30) (5.55) (1.80) (15.14)
’22 (5.25) (3.75) (6.15) (3.60) (18.59)
’21 (3.60) 1.35 (7.50) (4.66) (14.39)
’20 (5.26) (5.62) (7.53) (4.50) (22.51)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to August

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 2.40 8.10 22.50 10.65 5.10 6.41 27.00 9.74 18.00 6.90

Analyst estimates 2026–2028

Powerpack
High 10.50 63.90 76.20 50.63 16.80 187.50 74.10 53.93 102.75 36.45
People
People Employees — — — 8 4 6 7 5 7 7
Revenue/emp, $m 0.00 0.00 0.00 0.03 0.08 0.12 0.04 0.05 0.07 0.10
Income, $m
Income, $m Revenue 0 0 0 0 0 1 0 0 0 1
Gross margin, % (13.51) 50.94 94.18 89.71 68.42 75.74 71.89 86.07 98.97 99.62
EBT (1) (2) (7) (4) (4) (4) (7) (7) (6) (12)
EBT margin, % (3,138.08) (3,033.81) (1,525.32) (1,868.10) (1,317.92) (576.19) (2,891.03) (2,967.51) (1,251.07) (1,687.41)
Net income (1) 0 (7) (4) (4) (4) (7) (7) (6) (12)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.02 0.03 2.75 1.29 1.70 2.47 0.65 0.51 0.56 0.59
Earnings (0.90) (0.95) (41.93) (24.07) (22.51) (14.39) (18.59) (15.14) (7.05) (9.90)
Cash flow (0.40) (0.67) (15.98) (17.39) (14.16) (13.62) (12.43) (13.33) (6.00) (8.70)
Capex 0.00 0.00 (0.54) (4.45) (0.18) 0.66 (0.46) (0.38) (0.23) (0.08)
Free cash flow (0.40) (0.67) (16.52) (21.84) (14.34) (12.96) (12.89) (13.71) (6.23) (8.79)
Book value 0.16 1.53 15.15 14.41 13.42 44.60 19.45 6.07 9.27 2.17
Shares, m 2 2 0 0 0 0 0 0 1 1
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 22.37 15.18 6.10 37.81 68.21 30.73 97.40 22.60
P/B 0.00 0.51 4.06 1.36 0.77 2.09 2.28 2.59 5.90 6.13
EV/Sales 0.00 0.00 18.36 9.12 2.14 21.60 44.38 24.48 83.42 19.90
EV/FCF 0.00 0.00 (3.06) (0.54) (0.20) (4.10) (2.24) (0.91) (7.50) (1.33)
Cash, $m
Cash, $m Operating cash flow (1) (1) (3) (3) (3) (4) (5) (6) (5) (10)
Capex 0 0 0 (1) 0 0 0 0 0 0
Free cash flow (1) (1) (3) (4) (3) (4) (5) (6) (5) (11)
Balance, $m
Balance, $m Working capital 0 3 2 2 2 12 7 2 7 2
Total debt 0 0 0 — 0 0 0 0 — —
Net debt 0 (2) (2) (1) (1) (12) (6) (1) (7) (2)
Shareholders’ equity 0 3 2 2 2 13 8 3 8 3
Returns, %
Returns, % ROA (70.90) (659.83) (440.85) (162.85) (142.97) (50.04) (68.90) (122.09) (96.98) (182.50)
ROIC 0.00 0.00 (568.66) (156.74) (209.81) (269.29) (281.06) (339.63) (325.87) (1,168.81)
ROE (74.25) (114.25) (245.03) (170.46) (158.21) (51.81) (70.25) (129.26) (112.10) (231.96)
Negative figures in brackets.

All 10 years →

Fiscal years to Aug 2025 · latest quarter Feb 2026

Charts ten years each

Lexaria Bioscience Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
FBLG FibroBiologics Inc. $6.7M — (loss-making) — — n/m +21.59% (above 0%: growing) — 0.00% Compare
ACXP Acurx Pharmaceuticals, Inc. $6.5M — (loss-making) — — n/m −2.36% (below 0%: shrinking) — 0.00% Compare
TCRT Alaunos Therapeutics, Inc. $6.4M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m +57.20% (above 0%: growing) 100.00% 0.00% Compare
EVGN Evogene Ltd. $6.3M — (loss-making) — (loss-making) −35.02% (below 0%: shrinking) n/m +17.72% (above 0%: growing) 40.63% (738.62%) Compare
LEXX Lexaria Bioscience Corp. $6.3M — (loss-making) — (loss-making) −89.12% (below 0%: shrinking) n/m +53.90% (above 0%: growing) 100.00% 0.00%
ENVB Enveric Biosciences, Inc. $6.2M — (loss-making) — (loss-making) −7.28% (below 0%: shrinking) n/m −29.34% (below 0%: shrinking) 0.00% 0.00% Compare
TRAW Traws Pharma, Inc. $6.2M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −25.51% (below 0%: shrinking) 0.00% 0.00% Compare
ALZN Alzamend Neuro, Inc. $6.2M — (loss-making) — — n/m +51.82% (above 0%: growing) 0.00% 0.00% Compare
NRSN NeuroSense Therapeutics Ltd. $6.0M — (loss-making) — — n/m −23,458.82% (below 0%: shrinking) — 0.00% Compare
Median of peers $6.3M — — −21.15% — +7.68% 0.00% 0.00%

All 614 Biotechnology stocks →

Lexaria Bioscience Corp. (LEXX) key facts

  • Strength: Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024.
  • Lexaria Bioscience Corp. (LEXX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, LEXX traded at $2.92, a market capitalization of $6.3 million.
  • Return on equity was −232.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −23.89 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Lexaria Bioscience Corp. (LEXX) Latest News

21 Apr

Impact 5 ·
stockrow.com/LEXX · Data as of Feb 28, 2026 · For information only; not investment advice. · © 2026 stockrow.com